Effectiveness and Cost-Effectiveness of Non-Pharmacological Interventions among Chinese Adults with Prediabetes: A Protocol for Network Meta-Analysis and CHIME-Modeled Cost-Effectiveness Analysis

被引:1
|
作者
Yin, Yue [1 ,2 ]
Tu, Yusi [1 ,2 ]
Zhao, Mingye [1 ,2 ]
Tang, Wenxi [1 ,2 ]
机构
[1] China Pharmaceut Univ, Sch Int Pharmaceut Business, Dept Pharmacoecon, Nanjing 211198, Peoples R China
[2] China Pharmaceut Univ, Ctr Pharmacoecon & Outcomes Res, Nanjing 211198, Peoples R China
基金
中国国家自然科学基金;
关键词
prediabetes; non-pharmacological interventions; Chinese Hong Kong Integrated Modeling and Evaluation; cost-effectiveness; China; IMPAIRED GLUCOSE-TOLERANCE; DIABETES-MELLITUS; TYPE-2; PREVENTION; EXERCISE; PEOPLE;
D O I
10.3390/ijerph19031622
中图分类号
X [环境科学、安全科学];
学科分类号
08 ; 0830 ;
摘要
Patients with prediabetes who are at a high risk of progressing to diabetes are recommended early-stage intervention, according to guidelines. Non-pharmacological interventions are effective and cost-effective for glycemic control compared with medicines. We aim to explore which non-pharmacological interventions have the greatest potential effectiveness, cost-effectiveness, and feasibility in community-based diabetes management in China. We will perform a systematic review and network meta-analysis to compare the effectiveness of included non-pharmacological interventions, then use Chinese Hong Kong Integrated Modeling and Evaluation (CHIME) to model the yearly incidence of complications, costs, and health utility for the lifetime. Published studies (only randomized controlled trials (RCTs) and cluster RCTs with at least one study arm of any non-pharmacological intervention) will be retrieved and screened using several databases. Primary outcomes included blood glucose, glycated hemoglobin, incidence of type 2 diabetes mellitus, and achievement of normoglycemia. Health utilities and cost parameters are to be calculated using a societal perspective and integrated into the modified CHIME model to achieve quality-adjusted life-year (QALY) estimates and lifetime costs. QALYs and incremental cost-effectiveness ratio will then be used to determine effectiveness and cost-effectiveness, respectively. Our study findings can inform improved diabetes management in countries with no intervention programs for these patients.
引用
收藏
页数:12
相关论文
共 50 条
  • [21] Cost-effectiveness analysis and incremental cost-effectiveness ratios: uses and pitfalls
    Bambha, K
    Kim, WR
    [J]. EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY, 2004, 16 (06) : 519 - 526
  • [22] The Use of Meta-Analysis in Cost-Effectiveness AnalysisIssues and Recommendations
    Sanjay Saint
    David L. Veenstra
    Sean D. Sullivan
    [J]. PharmacoEconomics, 1999, 15 : 1 - 8
  • [23] The use of meta-analysis in cost-effectiveness analysis - Issues and recommendations
    Saint, S
    Veenstra, DL
    Sullivan, SD
    [J]. PHARMACOECONOMICS, 1999, 15 (01) : 1 - 8
  • [24] The value of supportive care: A systematic review of cost-effectiveness of non-pharmacological interventions for dementia
    Guzzon, Angelica
    Rebba, Vincenzo
    Paccagnella, Omar
    Rigon, Michela
    Boniolo, Giovanni
    [J]. PLOS ONE, 2023, 18 (05):
  • [25] Effectiveness and cost-effectiveness of telerehabilitation for musculoskeletal disorders: A systematic review and meta-analysis
    Molina-Garcia, Pablo
    Mora-Traverso, Marta
    Prieto-Moreno, Rafael
    Diaz-Vasquez, Andrea
    Antony, Benny
    Ariza-Vega, Patrocinio
    [J]. ANNALS OF PHYSICAL AND REHABILITATION MEDICINE, 2024, 67 (01)
  • [26] The effectiveness of cost-effectiveness analysis in containing costs
    Azimi, NA
    Welch, HG
    [J]. JOURNAL OF GENERAL INTERNAL MEDICINE, 1998, 13 (10) : 664 - 669
  • [27] The effectiveness of cost-effectiveness analysis in containing costs
    Nassir A. Azimi
    H. Gilbert Welch
    [J]. Journal of General Internal Medicine, 1998, 13 : 664 - 669
  • [28] Assessing the cost-effectiveness of precision medicine: protocol for a systematic review and meta-analysis
    Chen, Wenjia
    Anothaisintawee, Thunyarat
    Butani, Dimple
    Wang, Yi
    Zemlyanska, Yaroslava
    Wong, Chong Boon Nigel
    Virabhak, Suchin
    Hrishikesh, M. A.
    Teerawattananon, Yot
    [J]. BMJ OPEN, 2022, 12 (04):
  • [29] Medicare and cost-effectiveness analysis
    Neumann, PJ
    Rosen, AB
    Weinstein, MC
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2005, 353 (14): : 1516 - 1522
  • [30] WHAT IS COST-EFFECTIVENESS ANALYSIS
    EVANS, DB
    [J]. MEDICAL JOURNAL OF AUSTRALIA, 1990, 153 : S7 - S9